Overview

Tricaprilin in Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2007-01-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Accera, Inc.
Cerecin